Democrats Win. Pharma Braces for Change.

Good morning, ! Today we’re diving into how the U.S. midterm elections could reshape healthcare and pharma policy, Cinven’s €2.6B bet on women’s health, why healthcare’s biggest challenge is capacity rather than cost, and the latest wave of M&A across life sciences.

Want to advertise in Healthcare 150? Check out our ad platform, here.

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

— The Healthcare150 Team

MICROSURVEY

HEADLINE OF THE WEEK

Democrats Sweep Congress: Healthcare and Pharma Face a Policy Reset

Democrats have secured control of both the U.S. Senate and House of Representatives, fundamentally reshaping Washington’s political landscape and setting the stage for a potential shift in healthcare regulation, pharmaceutical pricing, and federal health spending. The November 3 midterm elections give Democrats greater leverage to challenge the Trump administration’s healthcare agenda.

For the pharmaceutical industry, the shift could renew pressure around prescription drug affordability, Medicare pricing, and industry oversight, potentially affecting pricing strategies and long-term revenue expectations. Meanwhile, Democrats are expected to prioritize reversing Medicaid funding cuts and restoring Affordable Care Act subsidies, developments that could reshape reimbursement dynamics for hospitals, insurers, and healthcare providers.

However, divided government and presidential veto powers may limit sweeping legislative changes, leaving healthcare companies navigating heightened policy uncertainty rather than immediate regulatory reform.

So What? Healthcare and pharmaceutical leaders face a changing policy environment in which drug pricing, reimbursement stability, and regulatory exposure could increasingly influence investment decisions, profitability, and long-term growth strategies. (More)

It's time to set up your holiday streaming campaign

Are you ready to reach holiday shoppers on CTV? For many streamers, the season is already underway.

Last year, according to Roku internal data, holiday content searches on Roku saw an 86% increase during October. And in November, those searches rise an average of 39% weekly. This surging holiday spirit is mirrored by consumer activity, as about half of Roku streamers shopped Black Friday and Cyber Monday deals in 2025.

Meeting those shoppers is easier than you might think. Begin with the seasonal outcome you hope to drive: awareness, online sales, leads, store visits, or another measurable goal. From there, define your audience, upload your creative, set the budget and campaign dates, and establish measurement before launching. You can even create a shoppable ad unit that lets streamers buy with a click of their remote.

Our holiday playbook offers a month-by-month guide to reaching shoppers during this all-important time of year.

First-time spenders get a $5,000 match on the first $5,000 spent with code BEEHIIV5K. Terms apply.

Launch your campaign today.

DEAL OF THE WEEK

Cinven's €2.6B Theramex Buyout: Private Equity Bets on Women's Health

Cinven has agreed to acquire Theramex, a women's health pharmaceutical company, from Carlyle and PAI Partners for approximately €2.6 billion. The transaction represents a significant PE exit, following the sellers' acquisition of the business for roughly €1.4 billion in 2022.

Operating in more than 80 countries, Theramex specializes in menopause, fertility, contraception, and osteoporosis. Under its previous owners, the company expanded its product portfolio and international footprint.

The deal underscores growing private equity interest in women's health, a historically underserved market with substantial unmet demand. For investors, Theramex illustrates how specialty pharma platforms can generate value through operational improvements, geographic expansion, and targeted acquisitions. (More)

TREND TO WATCH

Healthcare’s Biggest Problem Isn’t Cost. It’s Capacity.

Healthcare’s access crisis is becoming a structural constraint. According to an Ipsos survey spanning 30 countries, 47% of respondents identify treatment access and waiting times as a major healthcare problem, followed closely by staffing shortages (43%). The cost of treatment ranks third at 32%, suggesting that affordability is only part of a broader delivery challenge.

The underlying issue is capacity. Aging populations (23%) are adding pressure to healthcare demand, while bureaucracy (22%) compounds operational inefficiencies. Expanding coverage or lowering prices will have limited impact if health systems lack the workforce and infrastructure to deliver care.

Why it matters: For healthcare operators, the priority is shifting from expanding access on paper to increasing actual patient throughput. Workforce productivity, outpatient capacity, and administrative automation could become more valuable than traditional facility expansion.

For investors, the opportunity lies in businesses that address structural bottlenecks, particularly workforce management, ambulatory care, and workflow automation. However, adoption will depend on demonstrated improvements in capacity and unit economics.

Bottom line: Healthcare's next competitive advantage may not be delivering cheaper care, but delivering care sooner. (More)

DEALS TRACKER

Boehringer Ingelheim → Sino Biopharmaceutical oncology programs (option & license) | $358M upfront/near-term + up to $7B contingent payments
The agreement covers six preclinical ADC and T-cell engager programs. Announced Nov 4, it gives Boehringer options to license the assets after clinical milestones, extending big pharma’s push into Chinese oncology innovation. Read more

Cinven → Theramex, from Carlyle & PAI Partners | ~€2.6B reported; official terms undisclosed
Cinven agreed to acquire the women’s-health specialist on Nov 3, gaining a portfolio spanning menopause, osteoporosis, contraception and fertility in more than 80 countries. The sponsor-to-sponsor sale is expected to close in H1 2027. Read more · Reported value

Lonza → Merck KGaA’s US CDMO network | Low- to mid-triple-digit millions CHF EV
Lonza signed a definitive agreement, announced Nov 3, to acquire five manufacturing sites and approximately 1,100 employees. The carve-out more than doubles its US CDMO footprint to nine sites, adding capacity in bioconjugates, ADC payload-linkers and viral vectors. Read more

Rockwell Medical → Vantive’s hemodialysis business | $125M base + up to $45M contingent consideration
The Nov 3 agreement adds dialysis machines, concentrates, water-treatment systems and an Italian manufacturing campus. It would transform Rockwell into a broader global supplier, with projected combined annual revenue of $400M–$450M; closing is expected in mid-2027. Read more

INTERESTING ARTICLES